Overview
NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.
Last reviewed: 25 November 2020
Next review: We will review this decision if the company decides to make a submission.